» Articles » PMID: 1554844

Epidemiology of Poliomyelitis in the United States One Decade After the Last Reported Case of Indigenous Wild Virus-associated Disease

Overview
Journal Clin Infect Dis
Date 1992 Feb 1
PMID 1554844
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Poliomyelitis caused by wild poliovirus has been virtually nonexistent in the United States since 1980, and vaccine-associated paralytic poliomyelitis (VAPP) has emerged as the predominant form of the disease. We reviewed national surveillance data on poliomyelitis for 1960-1989 to assess the changing risks of wild-virus, vaccine-associated, and imported paralytic disease; we also sought to characterize the epidemiology of poliomyelitis for the period 1980-1989. The risk of VAPP has remained exceedingly low but stable since the mid-1960s, with approximately 1 case occurring per 2.5 million doses of oral poliovirus vaccine (OPV) distributed during 1980-1989. Since 1980 no indigenous cases of wild-virus disease, 80 cases of VAPP, and five cases of imported disease have been reported in the United States. Three distinct groups are at risk of vaccine-associated disease: recipients of OPV (usually infants receiving their first dose), persons in contact with OPV recipients (mostly unvaccinated or inadequately vaccinated adults), and immunologically abnormal individuals. Overall, 93% of cases in OPV recipients and 76% of vaccine-associated cases have been related to administration of the first or second dose of OPV. Our findings suggest that adoption of a sequential vaccination schedule (inactivated poliovirus vaccine followed by OPV) would be effective in decreasing the risk of VAPP while retaining the proven public health benefits of OPV.

Citing Articles

AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events.

Li Y, Li J, He J, Tao C PLoS One. 2024; 19(3):e0300919.

PMID: 38512919 PMC: 10956752. DOI: 10.1371/journal.pone.0300919.


Research Note: A Novel Sullivan Method Projection Framework With Application to Long COVID.

Ryan-Claytor C, Verdery A Demography. 2024; 61(2):267-281.

PMID: 38477520 PMC: 11824447. DOI: 10.1215/00703370-11226858.


Establishment of a Poliovirus Containment Program and Containment Certification Process for Poliovirus-Essential Facilities, United States 2017-2022.

Ottendorfer C, Shelby B, Sanders C, Llewellyn A, Myrick C, Brown C Pathogens. 2024; 13(2).

PMID: 38392855 PMC: 10893385. DOI: 10.3390/pathogens13020116.


Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?.

Devaux C, Pontarotti P, Levasseur A, Colson P, Raoult D Front Public Health. 2024; 11:1284337.

PMID: 38259741 PMC: 10801389. DOI: 10.3389/fpubh.2023.1284337.


A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.

Aldossary A, Ekweremadu C, Offe I, Alfassam H, Han S, Onyali V Saudi Pharm J. 2022; 30(6):655-668.

PMID: 35812139 PMC: 9257926. DOI: 10.1016/j.jsps.2022.03.010.